Last reviewed · How we verify
Mixed bipolar I disorder
Approved treatments
- Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Saphris · Hisamitsu
Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C. - Vraylar · AbbVie
Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior. - Tegretol · Novartis AG (originally Geigy)
Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain. - Zyprexa · Eli Lilly
- Risperdal · Johnson & Johnson (Janssen)
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder. - Geodon · Pfizer Inc.
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class. - Abilify · Generic (originally Otsuka/BMS)
Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it. - Carbamazepin · Enanta Pharmaceuticals, Inc
- Risperdal · Ohio State University
- Zyprexa · Washington University School of Medicine
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Mixed bipolar I disorder patent landscape — cliff calendar, originator estates, attackable patents
- Mixed bipolar I disorder treatment landscape brief
- Mixed bipolar I disorder treatment updates RSS
Frequently asked questions about Mixed bipolar I disorder
What drugs treat Mixed bipolar I disorder?
Tracked treatments include Abilify, Saphris, Vraylar, Tegretol, Zyprexa, Risperdal, Geodon, Carbamazepin.
What is the treatment for Mixed bipolar I disorder?
Standard treatment for Mixed bipolar I disorder includes Abilify, Saphris, Vraylar, Tegretol, Zyprexa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Mixed bipolar I disorder patent cliff · Mixed bipolar I disorder CI report
- Treatment: Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Treatment: Saphris · Hisamitsu
- Treatment: Vraylar · AbbVie
- Treatment: Tegretol · Novartis AG (originally Geigy)
- Treatment: Zyprexa · Eli Lilly
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing